Revenue segments as reported by the company.

Women’s Health

Biosimilars

Established Brands

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Acquired in-process research and development and milestones

Interest expense

Exchange losses (gains)

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Organon & Co

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Organon & Co reports strong Q4 earnings, eyes growth opportunities

Organon & Co's Q4 2022 earnings call highlighted robust financial performance, strategic initiatives in key segments, and a positive outlook for future growth. Despite challenges in China and market dynamics, the company remains focused on leveraging its strengths, addressing challenges, and capitalizing on growth opportunities to drive shareholder value and portfolio expansion.

Organon & Co reports solid Q1 performance and eyes growth opportunities

Organon & Co's Q1 2023 performance reflects revenue growth, margin improvement, and strategic investments in key franchises and medical devices.
The company's strengths lie in financial discipline, strong segment performance, and growth opportunities in fertility markets and biosimilars.
Challenges include inflationary pressures, competitive pricing scenarios, and the need to address loss of exclusivity and pricing dynamics.
Opportunities exist in expanding market presence in Asia Pacific, launching new products, and focusing on sustainable growth through financial prudence.

Organon & Co reports solid Q2 earnings, eyes growth opportunities

Organon & Co's Q2 2023 performance showed revenue growth, margin improvement, and strategic focus on key business segments.
Strengths in product differentiation, market positioning, and growth drivers position the company for continued success.
Challenges in revenue drivers, market expansion, and financial strategy require strategic adjustments for sustained growth.
Opportunities in Women's Health, biosimilar portfolio, and market penetration strategies offer avenues for future growth and market leadership.

Organon reports mixed Q3 results, eyes biosimilar growth opportunities

Organon's Q3 performance showed mixed results with challenges in women's health and biosimilar uptake, but stable growth in established brands.
The company is focusing on cost efficiency, portfolio optimization, and market expansion in biosimilars for future revenue growth.
Despite near-term challenges, Organon remains optimistic about its financial outlook, especially with opportunities in biosimilars and market expansion strategies.
Strategic shifts towards retail sector in China and product optimization are key focus areas for sustained growth and profitability.

Organon & Co reports solid Q4 earnings, eyes strategic growth

Organon's Q4 2023 earnings call showcased strong financials, strategic partnerships, and a focus on cost management. The company aims for low single-digit revenue growth in 2024 and $1 billion in free cash flow.

Organon & Co reports strong Q1 performance, eyes biosimilar growth

Organon & Co's Q1 2024 showcased robust revenue growth and strategic financial planning
Challenges include flat global fertility business and cautious outlook due to foreign exchange dynamics
Opportunities lie in expanding biosimilar market, margin expansion, and transformative deals

Organon & Co reports solid Q2 earnings, eyes franchise growth

Organon & Co's Q2 2024 performance reflects a mix of solid revenue growth and margin stability.
While facing challenges in certain regions and franchise segments, the company maintains a focus on growth.
Strategic opportunities lie in expanding key franchises, regulatory milestones, and operational efficiency.
Overall, Organon & Co remains optimistic about sustained revenue growth and financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cognizant Technology Solutions

Organon's Manufacturing Site Efficiencies Expected to Improve Supply Chain Management and Speed Healthcare Product Delivery TEANACK, N.J., July 21, 2022 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) today announced it has signed a new multi-year agreement with Organon (NYSE: OGN), a global women's health company, to help improve the company's delivery of healthcare products and crucial medicinal supply chain management.

Cognizant Teams Up with Organon to Speed Delivery of Pharmaceutical Products and Improve Women's Healthcare

Alpha Metallurgical Resources

MetLife

Packaging Corp of America

Exxon Mobil

While most stocks have nosedived this year, a few have gained altitude.

In a Sour Market, These Stocks Have Been Sweet

Viatris

Organon's P/E ratio was 6.5 at the end of Q1 2022, significantly lower than the pharmaceutical industry average. Viatris' revenue was $4,191.7 million in the first quarter of 2022, down 5.4% from a year earlier.

Organon Vs. Viatris: Who Is The Clear Winner?

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces first biosimilars business deal with a global license agreement with Henlius.

Organon Enters into Global License Agreement to Commercialize Henlius' Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #ESG--On one year anniversary, Organon introduces global ESG strategy & goals with the launch of Her Promise platform & publication of inaugural ESG report

On One Year Anniversary, Organon Introduces Global ESG Strategy and Commitments with Publication of Inaugural ESG Report

Organon & Co (NYSE:OGN ) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO & Director Matthew Walsh - EVP & CFO Conference Call Participants Jason Gerberry - Bank of America Merrill Lynch Terence Flynn - Morgan Stanley Eric Musonza - Evercore ISI Chris Shibutani - Goldman Sachs Group David Amsellem - Piper Sandler & Co. Gregory Fraser - Truist Securities Michael Nedelcovych - Cowen and Company Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Organon First Quarter 2020 Earnings Conference Call.

Organon & Co (OGN) CEO Kevin Ali on Q1 2022 Results - Earnings Call Transcript

Organon (OGN) delivered earnings and revenue surprises of 25.95% and 3.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Organon (OGN) Q1 Earnings and Revenues Beat Estimates

Organon easily beat first-quarter expectations Thursday despite a dive for its flagship product, Nexplanon, and OGN stock popped. The post Organon Easily Beats First-Quarter Expectations Despite Nexplanon Slip-Up appeared first on Investor's Business Daily.

Organon Easily Beats First-Quarter Expectations Despite Nexplanon Slip-Up

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) (the “company”), today announced its results for the first quarter ended March 31, 2022. "The first quarter marked a solid start to the year. We continued to expand our Women's Health offerings by acquiring the rights to Marvelon™ (ethinylestradiol, desogestrel) and Mercilon™ (ethinylestradiol, desogestrel) in certain markets, as well as by entering into a licensing agreement to commercialize XaciatoTM (clindamycin phosphate) vaginal gel,"

Organon Reports Results for the First Quarter Ended March 31, 2022

Biosimilar sales were $118 million in Q4 2021, up 14.6% from Q4 2020. Organon's dividend yield is around 3.5%, which is one of the largest in the pharmaceutical industry.

Organon: Maximum Optimism

Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Organon (OGN) is Poised to Beat Earnings Estimates Again

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon To Report First Quarter Results and Host Conference Call on May 5, 2022

Organon To Report First Quarter Results and Host Conference Call on May 5, 2022

Dare Bioscience

Organon & Co (NYSE: OGN) will license global rights to Daré Bioscience Inc's (NASDAQ: DARE) Xaciato (clindamycin phosphate vaginal gel, 2%).  Xaciato is an FDA-approved medication for treating bacterial vaginosis (BV) in females 12 years of age and.

Organon Inks Licensing Pact For Daré Bioscience's Bacterial Vaginosis Treatment

Citigroup

FedEx

With these shares at modest valuations, you can score some cheap long-term investments.

3 of the Best Value Stocks to Buy Heading Into April

Cowen

Organon & Co. (OGN) CEO Kevin Ali Presents at 42nd Annual Cowen Health Care Conference (Transcript)

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Cowen 42nd Annual Healthcare Virtual Conference on Wednesday, March 9, 2022 at 9:10 a.m. EST. Investors, analysts, members of the media and the general public are invited to watch to a live video webcast of the presentation at https://www.organon.com/investor-relations/events-and-prese

Organon To Present at the Cowen 42nd Annual Healthcare Virtual Conference

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Meghan Rivera Appointed US Managing Director, Organon

Meghan Rivera Appointed US Managing Director, Organon

Merck

Shares of Organon & Co. ( OGN , Financial) are up nearly 7% since the pharma company was spun off by Merck & Co. Inc. ( MRK , Financial) in the middle of 2021. And even bluer skies appear to be on the horizon as the company prepares to launch its version of the best-selling medication ever.

Organon Shares Up About 7% Since Merck Spinoff

Organon & Co. (OGN) CEO Kevin Ali on Q4 2021 Results - Earnings Call Transcript

Organon & Co's (NYSE: OGN) Q4 FY21 sales decreased 1% to $1.6 billion, beating the consensus of $1.57 billion. Women's Health increased 6%, driven primarily by Nexplanon, which increased 37% ex-FX.

Established Brands Hit Organon's Q4 Sales, Expects FY22 Sales Of Upto $6.4B

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon reports results for the fourth quarter and full year ended December 31, 2021

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2021

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon Acquires Marvelon® and Mercilon®, in the People's Republic of China, including Hong Kong, Macau, Agrees to Acquire these Products in Vietnam

Organon Acquires Contraceptive Products, Marvelon® and Mercilon®, in the People's Republic of China, including Hong Kong and Macau, and Agrees to Acquire these Products in Vietnam

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon to report 4th Quarter and full year 2021 earnings

Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 17, 2022

Organon is a spin-off from Merck that is focused on women's health, biosimilars, and established brands. The company's biosimilars are reporting growth and should see additional uptake. It has only been several months since Organon become a standalone company, and they are delivering on their objectives and hitting the Street's expectations.

News for Organon & Co Stock (OGN)